INmune Bio (NASDAQ:INMB – Get Free Report) posted its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports.
Here are the key takeaways from INmune Bio’s conference call:
- Positive sentiment: INmune Bio expects to submit its U.K. marketing authorization application for Ebstrocel in early February 2027, with potential approval around mid-2027. The company also targets a U.S. BLA submission in mid-2027, subject to FDA feedback.
- Positive sentiment: The MHRA has provided written alignment on planned clinical, non-clinical, and manufacturing elements, and the company says manufacturing and quality controls are being prepared for reliable supply. These steps support its application, but do not guarantee approval.
- Positive sentiment: A Uniphar agreement could enable named-patient access in eligible international markets before local approvals and create an earlier revenue opportunity. INmune cautioned that timing and scale depend on country-level arrangements, physician requests, and funding or reimbursement; no sales forecast was provided.
- Negative sentiment: INmune reported $16.3 million in cash at quarter-end and raised $4.5 million gross through an October stock-and-warrant offering, with cash expected to fund operations through Q3 2027. The company’s reduced quarterly loss and expenses were partly offset by the limited runway and potential share dilution.
INmune Bio Stock Performance
Shares of INmune Bio stock traded down $0.15 on Thursday, reaching $1.18. The stock had a trading volume of 469,848 shares, compared to its average volume of 265,973. The business’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $1.63. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $2.60. The stock has a market cap of $32.85 million, a P/E ratio of -1.75 and a beta of 0.97.
Wall Street Analyst Weigh In
A number of analysts have weighed in on INMB shares. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, INmune Bio has a consensus rating of “Moderate Buy”.
Read Our Latest Report on INMB
INmune Bio Company Profile
INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.
Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.
Further Reading
- Five stocks we like better than INmune Bio
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
